Black Diamond Therapeutics, Inc. - BDTX STOCK NEWS

Servier and Black Diamond Therapeutics (BDTX) have entered into a global licensing agreement for BDTX-4933, a Phase 1 targeted oncology therapy. The deal includes a $70 million upfront payment to Black Diamond, with potential additional payments of up to $710 million in development and commercial milestones, plus tiered royalties.

BDTX-4933 is designed as a potential best-in-class treatment targeting both RAS mutations and RAF alterations in solid tumors, including non-small cell lung cancer (NSCLC). The drug is currently in Phase 1 development, evaluating safety, tolerability, and antitumor activity in patients with recurrent advanced/metastatic cancers harboring BRAF, CRAF, or NRAS mutations.

Under the agreement, Servier will lead global development activities and commercialization of BDTX-4933 across multiple indications.

Black Diamond Therapeutics (BDTX) has reported its Q4 and full year 2024 financial results. The company ended 2024 with $98.6 million in cash and equivalents, projected to fund operations into Q4 2026. Net loss for Q4 2024 was $16.0 million, improved from $19.4 million in Q4 2023.

Key developments include anticipated Phase 2 clinical data for BDTX-1535 in Q2 2025 for first-line non-classical EGFRm NSCLC patients. The company plans to expand its 'window of opportunity' trial into newly diagnosed glioblastoma patients with EGFR aberrations in Q1 2025.

Financial metrics show R&D expenses decreased to $51.3 million in 2024 from $59.4 million in 2023, while G&A expenses slightly increased to $27.5 million from $27.1 million. Full-year net loss improved to $69.7 million compared to $82.4 million in 2023.

Black Diamond Therapeutics (BDTX) reported Q3 2024 financial results and corporate updates. The company announced encouraging Phase 2 data for BDTX-1535 in NSCLC patients, showing a 42% overall response rate in 19 patients with osimertinib resistance mutations. Cash position stood at $112.7 million as of September 30, 2024, expected to fund operations into Q2 2026. Q3 net loss improved to $15.6 million from $23.0 million year-over-year. The company implemented a corporate restructuring, deprioritizing BDTX-4933 to focus on BDTX-1535 development. Clinical updates and regulatory feedback are expected in Q1 2025.

Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies for cancer treatments, announced its upcoming participation in two major investor conferences. President and CEO Mark Velleca will present at the Stifel Healthcare Conference on November 19, 2024, at 4:10pm ET, and the Piper Sandler 36th Annual Healthcare Conference on December 4, 2024, at 3:00pm ET. Webcasts will be available on the company's website and archived for 90 days.

Black Diamond Therapeutics (Nasdaq: BDTX) announced a corporate restructuring to focus resources on advancing its lead program BDTX-1535 into pivotal development for EGFRm NSCLC. The company aims to extend its cash runway into Q2 2026. Key points include:

• Anticipates sharing initial Phase 2 data for BDTX-1535 in the frontline setting for EGFRm NSCLC in Q1 2025
• Plans to present updated Phase 2 results for BDTX-1535 in recurrent EGFRm NSCLC in Q1 2025
• Deprioritizing BDTX-4933 program and seeking potential partners
• Implementing a reduction in force while retaining core expertise
• Chief Business Officer, CFO, and Chief People Officer departing; Erika Jones appointed as Principal Financial Officer

The restructuring aims to optimize operations and focus investment on BDTX-1535, which has shown robust Phase 2 clinical activity in recurrent NSCLC patients with EGFR mutations.

Black Diamond Therapeutics has reported promising initial Phase 2 data for BDTX-1535 in patients with recurrent EGFRm NSCLC. Key findings include:

• A 200 mg daily dose selected for pivotal development, showing a favorable tolerability profile
• Preliminary ORR of 42% in 19 patients at 200 mg with on-target resistance EGFR mutations
• Encouraging durability with DOR of approximately 8 months or more for the first 3 patients with a PR
• 14 of 19 patients remain on treatment

The company anticipates regulatory feedback on the registration path in Q1 2025 and expects initial results of BDTX-1535 in first-line NSCLC patients with non-classical EGFR mutations in the same quarter.

Black Diamond Therapeutics (Nasdaq: BDTX), a clinical-stage oncology company, has announced a webcast presentation of initial Phase 2 clinical trial results for BDTX-1535 in patients with recurrent EGFRm NSCLC. The webcast is scheduled for Monday, September 23, 2024, at 8:00 a.m. ET.

Black Diamond specializes in developing MasterKey therapies targeting families of oncogenic mutations in cancer patients. The presentation will be accessible under the 'Events and Presentations' section of the company's website, with a replay available after the event.

Black Diamond Therapeutics (Nasdaq: BDTX) presented real-world treatment outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations (NCMs) at the ESMO Congress 2024. The study analyzed 3,276 cases from Guardant Health's database, revealing that 60% of NCM patients received chemotherapy/immunotherapy, while 36% received osimertinib or afatinib. Patients with NCMs showed shorter treatment duration compared to those with classical mutations. BDTX-1535, Black Diamond's fourth-generation EGFR TKI, aims to address a broad spectrum of EGFR mutations, including NCMs. The company plans to disclose initial Phase 2 data for BDTX-1535 in Q1 2025 for first-line NCM treatment and release second/third-line results later this month.

Black Diamond Therapeutics (Nasdaq: BDTX) reported Q2 2024 financial results and provided a corporate update. Key highlights include:

1. Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients expected in Q3 2024.

2. Phase 2 data of BDTX-1535 in 1L non-classical EGFRm NSCLC patients anticipated in Q1 2025.

3. Initial Phase 1 data of BDTX-4933 in KRASm NSCLC expected in Q4 2024.

4. Cash position of $123.0 million as of June 30, 2024, expected to fund operations into Q4 2025.

5. Q2 2024 net loss of $19.9 million, compared to $19.2 million in Q2 2023.

6. R&D expenses decreased to $12.6 million, while G&A expenses increased to $9.6 million in Q2 2024.